Objective To assess the association between covid-19 vaccines and risk of
thrombocytopenia and thromboembolic events in England among adults. Design Self …

Background Thrombosis with thrombocytopenia, or thrombocytopenia on its own, have been
reported after Covid-19 vaccines. We assessed the risk after ChAdOx1 adenovirus-vector …

We investigated thrombocytopenic, thromboembolic and hemorrhagic events following a
second dose of ChAdOx1 and BNT162b2 using a self-controlled case series analysis. We …

Objective To quantify the comparative risk of thrombosis with thrombocytopenia syndrome or
thromboembolic events associated with use of adenovirus based covid-19 vaccines versus …

Population-based studies can provide important evidence on the safety of COVID-19
vaccines. Here we compare rates of thrombosis and thrombocytopenia following vaccination …

Background Thromboses in unusual locations after the Coronavirus Disease 2019 (COVID-
19) vaccine ChAdOx1-S have been reported, although their frequency with vaccines of …

Reports of ChAdOx1 vaccine–associated thrombocytopenia and vascular adverse events
have led to some countries restricting its use. Using a national prospective cohort, we …

Importance Vaccinations are paramount to halt the COVID-19 pandemic, and safety data are
essential to determine the risk-benefit ratio of each COVID-19 vaccine. Objective To …

As with past illnesses, an approach has been taken to vaccinate the population and halt the
spread of COVID-19. On 13 April 2021, the US Food and Drug Administration called for a …

Despite early confusion over efficacy and the initial paucity of data in older age groups, 1 the
Oxford-AstraZeneca vaccine (ChAdOx1) has been shown to be highly effective, especially at …